RedHill Biopharma Ltd. RDHL
NASDAQ
Recommendation
Dividend Power Score
Day's Range
$0.41$0.45
Latest Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -96.44% | -48.57% | 55.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -96.44% | -48.57% | 55.30% |
| Cost of Revenue | -- | -- | -- | -- | -26.87% |
| Gross Profit | -- | -- | -90.50% | -90.50% | 214.50% |
| SG&A Expenses | -- | -- | -44.44% | 30.98% | -55.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -43.18% | -329.74% | -46.45% |
| Operating Income | -- | -- | 47.60% | 115.83% | 64.86% |
| Income Before Tax | -- | -- | -915.28% | 105.03% | 73.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -915.28% | 105.03% | 73.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 50.01% | 65.02% | 69.14% |
| EBIT | -- | -- | 47.60% | 115.83% | 64.86% |
| EBITDA | -- | -- | 49.43% | 125.15% | 64.53% |
| EPS Basic | -- | -- | 31.68% | 93.67% | 91.23% |
| Normalized Basic EPS | -- | -- | -656.87% | -82.68% | 94.40% |
| EPS Diluted | -- | -- | 31.68% | 93.67% | 91.23% |
| Normalized Diluted EPS | -- | -- | -656.87% | -82.68% | 94.40% |
| Average Basic Shares Outstanding | -- | -- | 41.01% | 26.50% | 97.35% |
| Average Diluted Shares Outstanding | -- | -- | 50.00% | 33.33% | 100.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |